Metformin has been a cornerstone in managing type 2 diabetes primarily known for its effects on the liver and gut. For over 60 years, it has been prescribed to help manage blood sugar levels in patients with this condition. Recent research, however, has unveiled new insights into how metformin operates within the brain, suggesting that its benefits may extend beyond metabolic control.
New findings indicate that metformin works in the brain by shutting down a protein called Rap1 in the ventromedial hypothalamus. This action activates SF1 neurons, which play a crucial role in energy balance and metabolism. According to researcher Makoto Fukuda, “This discovery changes how we think about metformin. It’s not just working in the liver or the gut, it’s also acting in the brain.”
Moreover, metformin is known for its potential health benefits beyond diabetes management. It has been associated with slowing brain aging and reducing wear and tear in the brain. A study conducted in 2025 revealed that metformin users had a 30% lower risk of dying before age 90 compared to those using sulfonylurea, a common alternative diabetes medication.
Fukuda further elaborated on the brain’s response to metformin, stating, “We found that while the liver and intestines need high concentrations of the drug to respond, the brain reacts to much lower levels.” This suggests that metformin’s efficacy in the brain may be achieved with smaller doses, potentially minimizing side effects.
Despite its benefits, metformin is not without drawbacks. Approximately 75% of those taking metformin experience gastrointestinal problems, which can limit its use for some patients. However, the ongoing research into its brain effects may provide new avenues for its application, particularly in geriatric medicine.
As metformin is increasingly recognized as a gerotherapeutic, capable of slowing down various aging processes in the body, its role in brain health is drawing attention. Observers anticipate that further studies will clarify the mechanisms by which metformin influences brain function and aging.
In light of these developments, healthcare professionals are encouraged to consider the broader implications of metformin therapy. The potential to reduce the risk of long COVID and other age-related cognitive declines could reshape treatment protocols for aging populations.
Details remain unconfirmed regarding the full extent of metformin’s impact on brain health, but the initial findings are promising. As research continues, the medical community is poised to explore metformin’s multifaceted role in health and longevity.
